Cite
Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.
MLA
Al Baghdadi, Tareq, et al. “Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology, vol. 3, Aug. 2019, pp. 1–8. EBSCOhost, https://doi.org/10.1200/PO.19.00124.
APA
Al Baghdadi, T., Halabi, S., Garrett-Mayer, E., Mangat, P. K., Ahn, E. R., Sahai, V., Alvarez, R. H., Kim, E. S., Yost, K. J., Rygiel, A. L., Antonelli, K. R., Butler, N. L., Bruinooge, S. S., & Schilsky, R. L. (2019). Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precision Oncology, 3, 1–8. https://doi.org/10.1200/PO.19.00124
Chicago
Al Baghdadi, Tareq, Susan Halabi, Elizabeth Garrett-Mayer, Pam K. Mangat, Eugene R. Ahn, Vaibhav Sahai, Ricardo H. Alvarez, et al. 2019. “Palbociclib in Patients With Pancreatic and Biliary Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.” JCO Precision Oncology 3 (August): 1–8. doi:10.1200/PO.19.00124.